Core Viewpoint - 康诺亚-B (02162) reported better-than-expected performance for the first half of the year, with Stapokibart sales reaching 169 million RMB, exceeding the previous guidance of 150 million RMB [1] Group 1: Financial Performance - Stapokibart sales amounted to 169 million RMB, surpassing the earlier forecast of 150 million RMB [1] - The company's focus on domestic product development strategies has led to some market disappointment despite the positive sales figures [1] Group 2: Market Outlook - The potential for CM512's secondary licensing opportunities has contributed to a recent increase in stock price [1] - Given the promising clinical progress of CM512 and its potential to become a best-in-class drug, the target price for 康诺亚 has been raised from 65 HKD to 78 HKD [1] - The rating for 康诺亚 has been adjusted from "highly confident to outperform the market" to "outperform the market" [1]
里昂：升康诺亚-B(02162)目标价至78港元 上半年业绩超预期